The FDA approved two drugs in Esperion's portfolio, and Daiichi Sankyo Europe received a milestone from Esperion, which has a collaboration with Otsuka in Japan.
1 report, 1 independent
Updated Aug 6
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA approved two drugs in Esperion's portfolio, and Daiichi Sankyo Europe received a milestone from Esperion, which has a collaboration with Otsuka in Japan.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
Esperion Therapeutics
American pharmaceutical company
Nothing else this week.
Related events
- OS Therapies, Inc. is seeking interim and final review data submissions from regulatory bodies while attending major global investment conferences.
- Amylyx Pharmaceuticals is seeking FDA approval for a new drug treatment.
- EyePoint Pharmaceuticals developed its LUCIA trial program in alignment with the FDA, with enrollment noted in Lugano.
- Solvonis Therapeutics plc is seeking FDA approval for its drug SVN-002 (esketamine) for the US market, utilizing YouTube for market updates.
- Inventiva seeks FDA approval for lanifibranor in the U.S. market.
Coverage
Newest first; wire copies grouped- ZacksESPR's Q2 Earnings & Revenues Trump Estimates, Stock Rises Esperion Therapeutics ESPR incurred a loss of 2 cents per share in the second quarter of 2025, which was much narrower than the Zacks Consen